Serge Jeandeau
A5051176201- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Respiratory Support and Mechanisms
- Frailty in Older Adults
- Lung Cancer Research Studies
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
Long-term changes in lung cancer (LC) patients are difficult to evaluate. We report results from the French KBP-2020 real-life cohort.KBP-2020 was a prospective cohort that included all diagnosed with LC 2020, nonacademic public hospital France. Patient and tumour characteristics were described compared similarly designed cohorts 2000 2010.In 82 centers 8,999 LC. The proportion of women increased: 34·6% (3114/8999) to, 24·3% (1711/7051) 16·0% (904/5667) 2010 (p<0·0001). non-smokers higher...
•Of 8827 patients with lung cancer included in the KBP-2020 study, 1792 (20.3%) were dead at 3 months after diagnosis.•Early mortality LC has decreased significantly over last 20 years but remained extremely high 2020.•Risk factors for 3-month similar to those reported other studies. BackgroundThe impact of most recent advances, including targeted therapies and immune checkpoint inhibitors, on early (3-month) is unknown. The aims this study evaluate real-world rate risk mortality, as well...
8059 Background: The KBP-CPHG studies are multicenter prospective real-life on LC, conducted in France each decade since 2000. We describe the characteristics of LC P50, which is a small population and rarely described [1 ], compare it to oldest with evolution Methods: All patients diagnosed 2020, non-academic public hospital were included KBP 2020. 8999 KBP-2020 have already been reported [ 2 ]. Only 428 (4.8%) P50 this cohort. Here, we their compared from over 50 years old previous cohorts...